Novartis, CH0012005267

Novartis signs USD 7.8 billion Abogen deal: 20 analysts rate Novartis stock Hold

Published on 10/05/2026 at 09:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Abogen receives USD 575 million upfront on October 2, 2026. Novartis stock costs EUR 126.25 on October 5, 2026 after EUR 125.36, plus 0.71 percent.

Draufsicht auf Tabletten, Blisterpacks, Beipackzettel und Stethoskop auf weißem Untergrund — Novartis AG CH0012005267 – Flatlay mit generischen Tabletten, Blister, Beipackzettel und Stethoskop auf Weiß, Illustration mit AI erstellt.

Novartis (ISIN CH0012005267) was trading at EUR 126.25 at Lang & Schwarz on October 5, 2026 at 9:12 a.m. CEST, up 0.71 percent versus the prior close of EUR 125.36. On October 2, 2026, Reuters reported that Novartis signed an agreement with Abogen worth up to USD 7.8 billion. MarketBeat lists 20 analyst ratings with a Hold consensus.

RNA deal expands pipeline options

The agreement gives Novartis exclusive worldwide rights to ABO2203, an experimental mRNA-encoded T-cell engager for autoimmune diseases, plus options on additional programs. Abogen will receive USD 575 million upfront and could earn up to USD 7.2 billion in development, regulatory and commercial milestones, according to CNBC.

The structure limits Novartis' initial cash commitment relative to the maximum deal value, while the clinical and regulatory milestones leave much of the payment conditional. Reuters quoted Gillian Hollenstein of Point Capital Navigator Fund describing the arrangement as having a better risk profile because the upfront payment is smaller, while also pointing to the need for later-stage deals with greater predictability.

Q2 growth meets generic pressure

Novartis reported USD 14.95 billion in revenue for the second quarter of 2026, operating profit of USD 4.75 billion and net income of USD 3.26 billion, according to ADVFN. The same report says revenue increased 3.00 percent in US dollars and 1.00 percent at constant exchange rates, while generic competition reduced growth by 14 percentage points.

The company also reaffirmed its full-year 2026 outlook for low single-digit revenue growth and a low single-digit decline in core operating income at constant exchange rates, as stated in the Novartis newsroom. That combination makes pipeline replacement the key valuation question after the Abogen announcement.

Stock stays above prior close

Novartis stock was trading at EUR 126.25 at Lang & Schwarz on October 5, 2026 at 9:12 a.m. CEST, versus the EUR 125.36 prior close from October 2, 2026. The primary listing is on SIX, where the stock closed at CHF 116.34 on October 2, 2026; the 52-week range was CHF 97.05 to CHF 132.68 and market capitalization was CHF 213.0 billion on that date. The further course of trading is shown by the continuously updated real-time quote of Novartis stock.